{"prompt": "['Trelagliptin-4002', 'Page 26 of 66', 'Version 2.0', 'July 5,10', '7.0', 'SELECTION AND WITHDRAWAL CRITERIA OF STUDY SUBJECTS', 'The principal investigator or investigator shall check for all the inclusion/exclusion criteria including', 'the test results prior to randomization.', '7.1', 'Inclusion criteria', 'Eligibility of study subjects shall be determined in accordance with the following criteria.', '1.', 'Patients diagnosed as type 2 diabetes.', '2.', 'Patients with a stable diet and exercise therapy only for at least 12 weeks prior to the start', 'of the screening period.', '3.', 'Patients who require a DPP-4 inhibitor treatment.', '4.', 'Patients with HbAlc_6.5% and <10.0 % at the start of the screening period.', '5.', 'Patients who completed DTR-QOL questionnaire at the start of the screening period.', '6.', 'Patients who have receive less than 2 types of medication for treatment of comorbidities', '(such as hypertension or dyslipidemia) at the start of the screening period (any number of', 'daily doses).', '7. Patients who, in the opinion of the principal investigator or the investigator, are capable of', 'understanding the content of the clinical study and complying with the study protocol', 'requirements.', '8.', 'Patients who can provide the written informed consent prior to the initiation of any study', 'procedures.', '9.', 'Patients aged >20 years at the time of informed consent.', '10. Outpatient.', '[Rationale for the inclusion criteria]', '1-3: These were set to specify a study subject applicable to achieve objective of this study.', '4:', 'The lower and upper limits were set to include a study subject whom treatment with oral', 'glucose-lowering medications is considered to require and who is suitable for', 'glucose-lowering monotherapy.', '5:', 'This was set because total score of DTR-QOL questionnaire at the start of the screening', 'period is stratifying factor of randomization.', '6:', 'This was set to minimize influences on drug taking behavior by medications for', 'comorbidities in the QOL study.', '7-10: These were set as fundamentals for this study.', '7.2', 'Exclusion criteria', 'Study subjects meeting any of the criteria below shall not be included in this study.', 'CONFIDENTIAL']['Trelagliptin-4002', 'Page 27 of 66', 'Version 2.0', 'July 5,10', '1.', 'Patients who are receiving any oral anti-diabetic medication for the treatment of type 2', 'diabetes at the start of the screening period.', '2.', 'Patients diagnosed as type 1 diabetes.', '3. Patients with severe renal impairment or renal failure (e.g., eGFR <30 mL/min/1.73 m\u00b2 or on', 'dialysis).', '4.', 'Patients with serious heart disease or cerebrovascular disorder, or serious pancreatic, blood, or', 'other disease.', '5. Patients with a history of gastrointestinal resection.', '6. Patient with a proliferative diabetic retinopathy.', '7. Patient with malignancy.', '8. Patients with a history of hypersensitivity or allergy to DPP-4 inhibitors.', '9.', 'Pregnant, lactating or postmenopausal women.', '10. Patients who may need to add or discontinue concomitant medication or change the dose', 'during the study period.', '11. Patients who will require treatment with a prohibited concomitant medication during the study', 'period.', '12. Patients participating in other clinical studies.', '13. Patients assessed ineligible in the study by the principal investigator or the investigator.', '[Rationale for the exclusion criteria]', '1, 10: These were set to exclude influences on senses of burden against treatment using', 'concomitant medications including diabetic medications other than the allocated oral', 'glucose-lowering medication.', '2:', 'This was set to exclude patients with type 1 diabetes, because the indications of', 'trelagliptin and daily DPP-4 inhibitors are for \"type 2 diabetes.\"', '3:', 'This was set to exclude patients with severe renal dysfunction or renal failure, because', 'trelagliptin is contraindicated in such patients.', '4-8, 11: These were set in consideration of patient safety.', '9:', 'This was set because trelagliptin should not be administered in pregnant or possibly', 'pregnant females unless potential therapeutic benefits outweigh risks, and because', 'excretion of trelagliptin and alogliptin into milk was observed in the non-clinical studies.', '12,13: These were set as fundamentals for this study.', 'CONFIDENTIAL']['Trelagliptin-4002', 'Page 28 of 66', 'Version 2.0', 'July 5,10', '7.3', 'Prohibited concomitant drugs and permitted concomitant drugs', 'The use of diabetic medications other than allocated oral glucose-lowering medication will', 'be prohibited during from the start of the screening period (Week -4) until the end of the', 'treatment period (Week 12).', '<Rationale of prohibited concomitant drugs>', 'It was designed due to potential influences on the assessment of this clinical study.', '7.4', 'Study subject management', 'The principal investigator and investigator shall instruct the research subject the items below.', '(1) Give instructions to take allocated oral hypoglycemic drug as directed.', '(2)', 'If hypoglycemia symptom (hunger abnormal, feeling of weakness, trembling of hands and', 'fingers, cold sweat, palpitations, etc.) is observed, take glucose or sucrose (sugar), and if it does', 'not improve give instructions to visit promptly.', '(3)', 'On visit days for planned laboratory tests, give instructions not to take oral hypoglycemic drug', 'scheduled to be taken on that day. Further, at each visit, have the research subject report if drug', 'has been taken or not the day before, and on the day of visit.', '(4) On visit days for planned laboratory tests, give instructions for fasting > 10 hours before visit', '(excluding start of observation period).', '(5) For research subjects of childbearing potential, give instructions to use adequate contraception.', 'If pregnancy is discovered, have the research subject report promptly, and discontinue the', 'research immediately.', '(6)', 'The principal investigator and investigator shall instruct the research subject to adhere to', 'instructed prohibited concomitant drugs. When drugs are taken other than the drugs prescribed', 'by the principal investigator and investigator, have the research subject report its content.', '(7) Regarding subjective symptoms/objective findings, have the research subject report at visit the', 'necessary items from its contents, onset date, degree, outcome and date of outcome.', '7.5', 'Criteria for discontinuation or withdrawal of a study subject', 'The principal investigator or investigator shall record the main reason for discontinuation of protocol', 'treatment on the case report form (CRF) according to the classification described below. Refer to', 'Section 9.1.15 for study subjects who withdraw from the study before randomization.', '1. Adverse events', 'When the study subject had an adverse event that requires withdrawal of the study subject from', 'the study because continued participation in the study would impose an unacceptable risk to the', 'CONFIDENTIAL']['Trelagliptin-4002', 'Page 29 of 66', 'Version 2.0', 'July 5,10', \"study subject's health, or when the study subject is unwilling to continue study participation\", 'because of the adverse event.', '2. Major protocol deviation', 'When it is discovered after randomization that a study subject does not meet the eligibility', 'criteria or is not adhering to the protocol, and continued participation in the study would impose', \"an unacceptable risk to the study subject's health.\", '3. Lost to follow-up', 'When the study subject failed to make visits and could not be contacted despite the attempts to', 'contact the study subject.', '4. Voluntary termination', 'When the study subject wishes to withdraw from the study. The reason for discontinuation shall', 'be obtained to the extent possible.', '5.', 'Study termination', 'When the sponsor or a committee such as the Ethical Review Board or regulatory authority has', 'decided to terminate the study. Refer to Section 6.3.1 for details.', '6. Pregnancy', 'When a female study subject was found to be pregnant.', 'Note: The study subject must discontinue the study immediately after she was found to be', 'pregnant. Refer to Section 9.1.13 for the procedures.', '7. Lack of efficacy', 'When efficacy of the study drug is not evident and continuation of the study may pose an', 'unacceptable risk to the study subjects in the opinion of the principal investigator or', 'investigator.', '8. Others', 'When the principal investigator or investigator determined to terminate the study for other', 'reasons.', 'The specific reasons should be recorded on the CRF.', '7.6', 'Procedures for discontinuation of individual study subjects', \"The principal investigator or investigator shall terminate a study subject's study participation when\", 'the study subject meets the criteria described in Section 7.5. Individual study subjects may', 'discontinue their study participation without giving a reason at any time during the study. Should a', 'CONFIDENTIAL']", "completion": ""}